Drugs / N2-L-Alanyl-L-Glutamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT03967795 | Nov 2019 → Mar 2023 | — | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01250782 Comparator | Oct 2010 → Sep 2012 | — | Hospital Universitari Son Dureta | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N2-L-Alanyl-L-Glutamine | “0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine” NCT01250782 ↗ |
| Modality | Peptide | “dipeptide N (2)-L-Alanyl-L-Glutamine” NCT01250782 ↗ |
| Route | Intravenous | “endovenous administration” NCT01250782 ↗ |